CSO, and biologist Dr. Max Plach works with a groundbreaking new technology for editing genes, called CRISPR-Cas9. The tool allows scientists to make precise edits to DNA strands, which could lead to ...

Researchers have been able to manipulate large chunks of genetic code for almost 50 years. But it is only within the past decade that they have been able to do it with exquisite precision – adding, ...

Over the past two decades, the immune system has attracted increasing attention for its role in fighting cancer. As researchers have learned more and more about the cancer-immune system interplay, ...

Scientists introduced CRISPR to the world as a gene-editing tool in summer 2012, when landmark papers from two independent groups demonstrated how the system could be wielded to make cuts in DNA. Now, ...

When scientists discovered how bacteria protect themselves against viral invaders, called phages, in the early 2000s, little did they know they’d stumbled upon a revolutionary tool researchers could ...

Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for ...

Nobel Prize winner and CRISPR DNA-editing pioneer Jennifer A. Doudna, PhD, spoke Thursday at Fred Hutch Cancer Center in Seattle. Her lecture kicked off the President’s Seminar series, presented by ...

St. Georges Technical High School students using CRISPR in a Box. On Friday, the US Food and Drug Administration approved a sickle cell disease drug called Casgevy, co-developed by Vertex ...

Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment opportunity for sickle cell disease and β-thalassemia. The discovery, ...

One of the most well-known versions of the gene-editing tool CRISPR may not work in a large proportion of the population, according to recent research out of Stanford University in California. CRISPR, ...

Possibly (indeed probably) a dumb question but why the relatively elaborate scheme to restart fetal haemoglobin expression, rather than repairing the defective HbA gene? I thought CRISPR/Cas editing ...